Secondary transcriptomic analysis of 272 patients with SLE in a phase 2 baricitinib trial: eight gene-expression endotypes were found, and significant SRI-4 response to baricitinib vs placebo was confined to endotypes D and G.
RCTn = 272
Bachali et al. Subsets of Patients With Lupus Identified by Gene Expression Profiles Exhibit Differential Clinical Responsiveness to Baricitinib